CSF3 and acute myeloid leukemia: We suppose that the cell-lineage specificity may be exploitable for a possible targeted therapeutic approaches for distinct AL types (i.e., AML, T-ALL, BCP-ALL), particularly PHA administered in encapsulated form, stimulating G-CSF production.